Epizyme Inc

Epizyme is a clinical stage biopharmaceutical company that is focused on the treatment of cancer and other diseases through discovering, developing, and commercializing epigenetic medicines. The company is developing its primary product candidate, tazemetostat, an oral selective inhibitor of the EZH2 histone methyltransferase in a range of cancer types and settings, and developing the primary development candidate in its G9a program, EZM8266, for the treatment of sickle cell disease. The company also has a pipeline of drug discovery programs that target its other chromatin modifying proteins. These programs are directed to specific cancers, including both hematological malignancies and solid tumors.
  • TickerEPZM
  • ISINUS29428V1044
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Shrimp on the Barbie for Taz(y) Three days before OZ Day, PDUFA on 23 Jan 2020

1 director sold

A director at Epizyme Inc sold 104,944 shares at 13.082USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch